AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 188 filers reported holding AKERO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $61,792,271 | +10.1% | 1,221,674 | +1.7% | 3.15% | +3.9% |
| Q2 2023 | $56,102,284 | +13.7% | 1,201,591 | -6.8% | 3.03% | +55.5% |
| Q1 2023 | $49,339,752 | -49.9% | 1,289,591 | -28.2% | 1.95% | -55.2% |
| Q4 2022 | $98,388,194 | +32.9% | 1,795,405 | -17.5% | 4.36% | -4.7% |
| Q3 2022 | $74,057,000 | +316.2% | 2,174,946 | +15.5% | 4.57% | +349.6% |
| Q2 2022 | $17,792,000 | -19.3% | 1,882,698 | +21.2% | 1.02% | +1.1% |
| Q1 2022 | $22,037,000 | -32.8% | 1,552,990 | +0.1% | 1.01% | -39.9% |
| Q4 2021 | $32,806,000 | -3.5% | 1,551,090 | +2.0% | 1.67% | 0.0% |
| Q3 2021 | $33,999,000 | -8.6% | 1,521,190 | +1.5% | 1.67% | +11.8% |
| Q2 2021 | $37,189,000 | +377.8% | 1,498,938 | +458.7% | 1.50% | +324.1% |
| Q1 2021 | $7,783,000 | – | 268,282 | – | 0.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $179,512,000 | 24.20% |
| venBio Partners LLC | 2,444,311 | $75,260,000 | 11.44% |
| Versant Venture Management, LLC | 777,727 | $23,946,000 | 4.38% |
| Redmile Group, LLC | 2,336,357 | $71,936,000 | 1.32% |
| Vivo Capital, LLC | 571,833 | $17,607,000 | 1.02% |
| Cormorant Asset Management, LP | 859,550 | $26,466,000 | 1.02% |
| Boxer Capital, LLC | 831,495 | $25,602,000 | 0.88% |
| Integral Health Asset Management, LLC | 85,000 | $2,617,000 | 0.80% |
| EAM Global Investors LLC | 49,718 | $1,531,000 | 0.56% |
| Crawford Lake Capital Management, LLC | 43,826 | $1,349,000 | 0.56% |